Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation

In a recent study published in the Journal of American Medical Association (JAMA), researchers from the United States of America (US) examined the prevalence of the self-reported use of Δ8-tetrahydrocannabinol (THC) and marijuana among adolescents in the US. They found that the prevalence of Δ8-THC and marijuana use was remarkable among adolescents and higher in states lacking Δ8-THC regulations or marijuana legalization.

Study: Adolescent Δ8-THC and Marijuana Use in the US. Image Credit: Kitreel / ShutterstockStudy: Adolescent Δ8-THC and Marijuana Use in the US. Image Credit: Kitreel / Shutterstock

Background

Δ8-THC, a psychoactive compound and isomer of Δ9-THC found in marijuana, is derived from hemp and legally available since the 2018 Agriculture Improvement Act. Commercially manufactured consumable hemp-derived Δ8-THC products such as edibles and vaping devices have proliferated, potentially posing risks to adolescents, such as addiction and neurodevelopmental changes.

There is a dearth of data on the use of Δ8-THC among adolescents, hampering policy development. Δ8-THC products lack a federal minimum purchasing age and are available online and in stores without stringent age verification, potentially increasing adolescent access. This access may be more pronounced in states lacking Δ8-THC regulations or where adult-use marijuana is illegal, as Δ8-THC is marketed as a legal alternative. Therefore, researchers in the present study aimed to estimate the self-reported Δ8-THC or marijuana use prevalence among 12th-grade US students, considering state-level cannabis policies and sociodemographic factors. They aimed to provide insights for policymaking in public health.

About the study

As a part of the Monitoring the Future (MTF) survey conducted in 2023, a total of 2,186 randomly selected 12th-grade students were questioned regarding the use of Δ8-THC. The average age of the participants was 17.7 years, and the sample included 48.9% females, 45.8% males, and 5.3% other or unreported sex. The sample represented the following races: Asian (4%), Black (11.1%), Hispanic (23.5%), White (46.1%), multiracial (14.2%), and others (1.1%). Geographically, the participants resided in the following regions of the country: South (36.7%), West (24.5%), Midwest (22%), and Northeast census regions (16.9%). While a majority of participants (44.2%) lived in states with the legalization of adult-use marijuana, 34.8% of them lived in states with Δ8-THC regulations.

Participants reported the frequency of Δ8-THC and marijuana use in the past year. Data included sex, race/ethnicity, parental education, and school location. State-level policies on Δ8-THC and adult-use marijuana were considered and classified. Δ8-THC and marijuana use prevalence were calculated and stratified by sociodemographic and policy variables. Adjusted risk ratios (aRRs) were estimated using log-binomial models, controlling for relevant factors. Sensitivity analyses and weighted analyses were conducted. Differences in aRRs between Δ8-THC and marijuana use were evaluated. However, the researchers did not correct for multiple testing in this exploratory study.

Results and discussion

As per the study, in the last year, around 11.4% of adolescents (n= 295) reported using Δ8-THC. Among these users, 68.1% used it at least thrice, 35.4% at least 10 times, and 16.8% of participants used Δ8-THC at least 40 times. About 90.7% of the participants also reported using marijuana. The prevalence was found to be similar among males (12.3%) and those with other or unreported genders (19.7%), while females showed a slightly lower prevalence (9.6%). However, the sex-based differences were not statistically significant. Hispanic participants showed a significantly lower prevalence compared to White participants (7.3% vs. 14.4%). Additionally, the prevalence was found to be 9.7% among Black participants, 9.6% among Asians, 10.3% among multiracial participants, and 7.2% in other races. No significant differences were observed based on parental education.

Over 12 months, Δ8-THC use was found to vary across US census regions: 14.3% in the South, 14.6% in the Midwest, 10.1% in the Northeast, and 5.0% in the West. The prevalence was significantly lower in the West compared to the South (aRR = 0.35). Furthermore, Δ8-THC use was found to be significantly higher in the Midwest than in the West. Interestingly, states with adult-use marijuana legalization showed a lower prevalence compared to those without (aRR = 0.56). Similarly, states with Δ8-THC regulation showed lower prevalence (5.7%) compared to those without (14.4%).

The overall prevalence of marijuana use in the past year was 30.4%. White participants showed a higher prevalence (33.0%) compared to Hispanic participants (24.5%). No significant differences were observed with respect to sex or parental education. In adjusted models, marijuana use was found to be lower in the South than in the Northeast region. State-level cannabis policies did not show variations in marijuana use. The aRRs for the Census region and cannabis policy were found to be significantly different for Δ8-THC and marijuana use. Sensitivity analysis confirmed the main findings of the study.

The study is limited by correlated variables of census region and state-level policy, incomplete state representation in the survey sample, exclusion of non-enrolled or absent students, potential age bias toward older adolescents, and lack of measurement for other hemp-derived products, possibly underestimating adolescent Δ8-THC use.

Conclusion

In conclusion, adolescent Δ8-THC use is considerable in the US, especially in states lacking marijuana legalization or specific Δ8-THC regulations. The study highlights the importance of focusing on surveillance, policy, and public health efforts to urgently address Δ8-THC use among adolescents.

Journal reference:
Dr. Sushama R. Chaphalkar

Written by

Dr. Sushama R. Chaphalkar

Dr. Sushama R. Chaphalkar is a senior researcher and academician based in Pune, India. She holds a PhD in Microbiology and comes with vast experience in research and education in Biotechnology. In her illustrious career spanning three decades and a half, she held prominent leadership positions in academia and industry. As the Founder-Director of a renowned Biotechnology institute, she worked extensively on high-end research projects of industrial significance, fostering a stronger bond between industry and academia.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chaphalkar, Sushama R.. (2024, March 13). Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20240313/ce94-8-Tetrahydrocannabinol-use-among-US-teens-climbs-in-states-without-regulation.aspx.

  • MLA

    Chaphalkar, Sushama R.. "Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20240313/ce94-8-Tetrahydrocannabinol-use-among-US-teens-climbs-in-states-without-regulation.aspx>.

  • Chicago

    Chaphalkar, Sushama R.. "Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation". News-Medical. https://www.news-medical.net/news/20240313/ce94-8-Tetrahydrocannabinol-use-among-US-teens-climbs-in-states-without-regulation.aspx. (accessed October 31, 2024).

  • Harvard

    Chaphalkar, Sushama R.. 2024. Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20240313/ce94-8-Tetrahydrocannabinol-use-among-US-teens-climbs-in-states-without-regulation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cannabis use linked to thinning cerebral cortex in adolescents